EADV

Dermatologists play a vital role in creating safe, inclusive spaces for LGBTQIA+ patients. In this interview, Assistant Professor Teerapong Rattananukrom explores why inclusive language matters, the unique skin challenges faced by transgender individuals, and how greater representation in research can help shape more equitable, compassionate care.

Ultra-high frequency ultrasound is emerging as a valuable tool in the management of alopecia areata (AA). Beyond its established role in visualising hair follicle and scalp structures, it is now being explored for diagnosing AA, distinguishing it from other types of hair loss, and monitoring disease progression across different stages. Crucially, this non-invasive imaging technique also shows promise in predicting and tracking treatment responses, paving the way for more personalised care strategies for patients receiving targeted therapies.

Each year, the EADV offers a funded EADV Clinical Fellowship & Research Fellowship programme designed to provide additional opportunities and support for young dermatologists, trainees and junior scientists. These initiatives aim to help individuals gain hands-on experience, expand their skills and broaden their knowledge of dermatology and venereology in leading European centres. However, it can sometimes be difficult to know exactly what these opportunities involve, or whether they are the right fit for you. To help answer that question, there is no better way than to hear directly from someone with first-hand experience. This year, Dr Flavia Manzo Margiotta (University of Pisa, Italy) was awarded the EADV Clinical Fellowship, gaining valuable experience at Städtisches Klinikum Dessau under the expert guidance of Prof. Christos Zouboulis, Dr Georgios Nikolakis, and colleagues.

Drug-resistant fungal skin infections are an emerging global health concern, with cases increasingly reported across continents. These infections are more difficult-to-treat fungal, often require prolonged therapy, and are associated with higher rates of recurrence. To help address this growing problem, it is important to understand the factors driving resistance, explore potential solutions to limit the spread of these organisms and recognise the challenges involved in implementing effective control strategies. To explore some of these factors, we spoke with Dr Olufolakemi Cole-Adeife (Lagos, Nigeria), who presented her research on this topic ‘Recalcitrant Fungal Skin Infections and Possible Links with Topical Corticosteroid and Antiseptic Misuse in Nigeria: A Case Series’ at the EADV Congress 2025. In this discussion, Dr. Cole shares insights into her findings and the wider implications for clinical practice and public health.

Laser and energy based devices are transforming dermatology, offering increasingly advanced ways to treat a wide range of conditions from pigment disorders and tattoo removal to skin rejuvenation and aesthetic enhancement. As the technology evolves, so too does our understanding of how to use it most effectively in clinical practice. At the same time, the field faces significant challenges, including the influence of marketing and the importance of selecting these technologies appropriately.

At the EADV Congress 2025, an analysis from Atopic Eczema Systemic Therapy Register (A STAR) was presented exploring the association between systemic medications used in patients with atopic eczema and the achievement of super response. We were delighted to speak with Prof. Carsten Flohr (London, UK) to learn more.

The EADV 2025 Congress in Paris showcased the latest research and treatment advances in dermatology. To highlight the most important updates in both paediatric and adult atopic dermatitis, we spoke with Professor Carsten Flohr, a leading expert from London, UK.

Skin neglected tropical diseases (NTDs), including leprosy, lymphatic filariasis and onchocerciasis, remain a significant public health challenge in many low- and middle-income countries. Frontline healthcare workers often struggle to recognise and manage these conditions due to limited diagnostic tools and gaps in specialist training. In this interview, we speak with Dr Olufolakemi Cole-Adeife (Lagos, Nigeria) about a virtual training programme designed to overcome these barriers.

For patients with moderate-to-severe plaque psoriasis (PsO), high efficacy with a favourable safety profile is generally only achieved with injectable therapies. Icotrokinra is an investigational oral therapy that has shown promising early efficacy and safety in adults and adolescents with moderate-to-severe plaque PsO in the phase 3 ICONIC-LEAD study (NCT06095115). At EADV 2025 (held in Paris, France, 17–20 September 2025), we spoke with Dr Jennifer Soung (Santa Ana, CA, USA), who presented the longer-term clinical response and safety findings through week 52 of the ICONIC-LEAD study.